

PI:					
BL1-N	APPENDIX Q. PHYSICAL AND BIOLOGICAL CONTAINMENT FOR RECOMBINANT DNA RESEARCH INVOLVING ANIMALS Jan. 2011	N/A	Conform	Non-Conform	Comments
	Appendix Q-I. General Considerations				
	Appendix Q-I-A. Containment Levels				
	The containment levels required for research involving recombinant DNA associated with or in animals is based on classification of experiments in Section III, Experiments Covered by the NIH Guidelines. For the purpose of animal research, four levels of containment are established. These are referred to as BL1-Animals (N), BL2-N, BL3-N, and BL4-N and are described in the following appendices of Appendix Q. The descriptions include: (i) standard practices for physical and biological containment, and (ii) animal facilities.				
	Appendix Q-I-B. Disposal of Animals (BL1-N through BL4-N)				
	Appendix Q-I-B-1. When an animal covered by Appendix Q containing recombinant DNA or a recombinant DNA-derived organism is euthanized or dies, the carcass shall be disposed of to avoid its use as food for human beings or animals unless food use is specifically authorized by an appropriate Federal agency.				
	Appendix Q-I-B-2. A permanent record shall be maintained of the experimental use and disposal of each animal or group of animals.				
	Appendix Q-II. Physical and Biological Containment Levels				
	Appendix Q-II-A. Biosafety Level 1 - Animals (BL1-N)				
	Appendix Q-II-A-1. Standard Practices (BL1-N)				
	Appendix Q-II-A-1-a. Animal Facility Access (BL1-N)				
	Appendix Q-II-A-1-a-(1). The containment area shall be locked.				
	Appendix Q-II-A-1-a-(2). Access to the containment area shall be limited or restricted when experimental animals are being held.				
	Appendix Q-II-A-1-a-(3). The containment area shall be patrolled or monitored at frequent intervals.				
	Appendix Q-II-A-1-b. Other (BL1-N)				
	Appendix Q-II-A-1-b-(1). All genetically engineered neonates shall be permanently marked within 72 hours after birth, if their size permits. If their size does not permit marking, their containers should be marked. In addition, transgenic animals should contain distinct and biochemically assayable DNA sequences that allow identification of transgenic animals from among non-transgenic animals.				

Appendix Q-II-A-1-b-(2) A double barrier shall be provided to separate male and female animals unless reproductive studies are part of the experiment or other measures are taken to avoid reproductive transmission. Reproductive incapacitation may be used.				
Appendix Q-II-A-1-b-(3). The containment area shall be in accordance with state and Federal laws and animal care requirements.				
Appendix Q-II-A-2. Animal Facilities (BL1-N)				
Appendix Q-II-A-2-a. Animals shall be confined to securely fenced areas or be in enclosed structures (animal rooms) to minimize the possibility of theft or unintentional release.				
Appendix Q-II-B. Biosafety Level 2 - Animals (BL2-N) (See Appendix Q-III-A, Footnotes and References for Appendix Q)				
Appendix Q-II-B-1. Standard Practices (BL2-N)				
Appendix Q-II-B-1-a. Animal Facility Access (BL2-N)				
Appendix Q-II-B-1-a-(1). The containment area shall be locked.				
Appendix Q-II-B-1-a-(2). The containment area shall be patrolled or monitored at frequent intervals.				
Appendix Q-II-B-1-a-(3). The containment building shall be controlled and have a locking access.				
Appendix Q-II-B-1-a-(4). The Animal Facility Director shall establish policies and procedures whereby only persons who have been advised of the potential hazard and who meet any specific entry requirements (e.g., vaccination) may enter the laboratory or animal rooms.				
Page 124 - NIH Guidelines for Research Involving Recombinant DNA Molecules (January 2011)				
Appendix Q-II-B-1-a-(5). Animals of the same or different species, which are not involved in the work being performed, shall not be permitted in the animal area.				
Appendix Q-II-B-1-b. Decontamination and Inactivation (BL2-N)				
Appendix Q-II-B-1-b-(1). Contaminated materials that are decontaminated at a site away from the laboratory shall be placed in a closed durable leak-proof container prior to removal from the laboratory.				
Appendix Q-II-B-1-b-(2). Needles and syringes shall be promptly placed in a puncture-resistant container and decontaminated, preferably by autoclaving, before discard or reuse.				
Appendix Q-II-B-1-c. Signs (BL2-N)				

<p>Appendix Q-II-B-1-c-(1). When the animal research requires special provisions for entry (e.g., vaccination), a warning sign incorporating the universal biosafety symbol shall be posted on all access doors to the animal work area. The sign shall indicate: (i) the agent, (ii) the animal species, (iii) the name and telephone number of the Animal Facility Director or other responsible individual, and (iv) any special requirements for entering the laboratory.</p>				
<p>Appendix Q-II-B-1-d. Protective Clothing (BL2-N)</p>				
<p>Appendix Q-II-B-1-d-(1). Laboratory coats, gowns, smocks, or uniforms shall be worn while in the animal area or attached laboratory. Before entering non-laboratory areas (e.g., cafeteria, library, administrative offices), protective clothing shall be removed and kept in the work entrance area.</p>				
<p>Appendix Q-II-B-1-d-(2). Special care shall be taken to avoid skin contamination with microorganisms containing recombinant DNA. Impervious and/or protective gloves shall be worn when handling experimental animals and when skin contact with an infectious agent is unavoidable.</p>				
<p>Appendix Q-II-B-1-e. Records (BL2-N)</p>				
<p>Appendix Q-II-B-1-e-(1). Any incident involving spills and accidents that result in environmental release or exposures of animals or laboratory workers to organisms containing recombinant DNA molecules shall be reported immediately to the Animal Facility Director, Institutional Biosafety Committee, NIH/OBA, and other appropriate authorities (if applicable). Reports to the NIH/OBA shall be sent to the Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985 (20817 for non-USPS mail), 301-496-9838, 301-496-9839 (fax). Medical evaluation, surveillance, and treatment shall be provided as appropriate and written records maintained. If necessary, the area shall be appropriately decontaminated.</p>				
<p>Appendix Q-II-B-1-e-(2). When appropriate and giving consideration to the agent handled, baseline serum samples shall be collected and stored for animal care and other at-risk personnel. Additional serum specimens may be collected periodically depending on the agent handled and the function of the animal facility.</p>				
<p>Appendix Q-II-B-1-f. Transfer of Materials (BL2-N)</p>				

<p>Appendix Q-II-B-1-f-(1). Biological materials removed from the animal containment area in a viable or intact state shall be transferred to a non-breakable sealed primary container and then enclosed in a non-breakable sealed secondary container. All containers, primary and secondary, shall be disinfected before removal from the animal facility. Advance approval for transfer of material shall be obtained from the Animal Facility Director. Packages containing viable agents may only be opened in a facility having an equivalent or higher level of physical containment unless the agent is biologically inactivated or incapable of reproduction.</p>				
<p>Page 125 - NIH Guidelines for Research Involving Recombinant DNA Molecules (January 2011)</p>				
<p>Appendix Q-II-B-1-g. Other (BL2-N)</p>				
<p>Appendix Q-II-B-1-g-(1). All genetically engineered neonates shall be permanently marked within 72 hours after birth, if their size permits. If their size does not permit marking, their containers should be marked. In addition, transgenic animals should contain distinct and biochemically assayable DNA sequences that allow identification of transgenic animals from among non-transgenic animals.</p>				
<p>Appendix Q-II-B-1-g-(2). Needles and syringes shall be used only for parenteral injection and aspiration of fluids from laboratory animals and diaphragm bottles. Only needle-locking syringes or disposable syringe-needle units (i.e., needle is integral to the syringe) shall be used for the injection or aspiration of fluids containing organisms that contain recombinant DNA. Extreme caution shall be used when handling needles and syringes to avoid autoinoculation and the generation of aerosols during use and disposal. Following use, needles shall not be bent, sheared, replaced in the needle sheath or guard, or removed from the syringe. Needles and syringes shall be promptly placed in a puncture-resistant container and decontaminated, preferably by autoclaving, before discard or reuse.</p>				
<p>Appendix Q-II-B-1-g-(3). Appropriate steps should be taken to prevent horizontal transmission or exposure of laboratory personnel. If the agent used as a vector is known to be transmitted by a particular route (e.g., arthropods), special attention should be given to preventing spread by that route. In the absence of specific knowledge of a particular route of transmission, all potential means of horizontal transmission (e.g., arthropods, contaminated bedding, or animal waste, etc.) should be prevented.</p>				
<p>Appendix Q-II-B-1-g-(4). Eating, drinking, smoking, and applying cosmetics shall not be permitted in the work area.</p>				

	Appendix Q-II-B-1-g-(5). Individuals who handle materials and animals containing recombinant DNA molecules shall be required to wash their hands before exiting the containment area.				
	Appendix Q-II-B-1-g-(6). A double barrier shall be provided to separate male and female animals unless reproductive studies are part of the experiment or other measures are taken to avoid reproductive transmission. Reproductive incapacitation may be used.				
	Appendix Q-II-B-1-g-(7). The containment area shall be in accordance with state and Federal laws and animal care requirements.				
	Appendix Q-II-B-1-g-(8). A biosafety manual shall be prepared or adopted. Personnel shall be advised of special hazards and required to read and follow instructions on practices and procedures.				
	Appendix Q-II-B-2. Animal Facilities (BL2-N)				
	Appendix Q-II-B-2-a. Animals shall be contained within an enclosed structure (animal room or equivalent) to minimize the possibility of theft or unintentional release and to avoid arthropod access. The special provision to avoid the entry or escape of arthropods from the animal areas may be waived if the agent in use is not known to be transmitted by arthropods.				
	Appendix Q-II-B-2-b. Surfaces shall be impervious to water and resistant to acids, alkalis, organic solvents, and moderate heat.				
	Appendix Q-II-B-2-c. The animal containment area shall be designed so that it can be easily cleaned.				
	Appendix Q-II-B-2-d. Windows that open shall be fitted with fly screens.				
	Appendix Q-II-B-2-e. An autoclave shall be available for decontamination of laboratory wastes.				
	Appendix Q-II-B-2-f. If arthropods are used in the experiment or the agent under study can be transmitted by an arthropod, interior work areas shall be appropriately screened (52 mesh). All perimeter joints and openings shall be sealed and additional arthropod control mechanisms used to minimize arthropod entry and propagation, including appropriate screening of access doors or the equivalent.				